The development of medications aimed at preserving muscle mass and enhancing fat loss when used alongside GLP-1 receptor agonists for weight loss is a growing area of interest. Drugs like semaglutide and GIP/GLP-1 tirzepatide are showing promising weight loss results, but concern has arisen about the impact on lean body mass vs fat mass. Several drugs in development, such as Veru Inc.’s enobosarm and Scholar Rock’s apitegromab, are being explored for their potential to preserve or build muscle mass while boosting fat loss. Research is ongoing to determine the functional benefits and safety of these combination therapies, particularly in older adults with sarcopenic obesity. Studies at this year’s American Association of Clinical Endocrinology meeting laid the groundwork for further investigation into these muscle-preserving medications in combination with GLP-1 agonists. While the potential benefits are promising, caution is advised regarding potential risks and maintaining a focus on overall health outcomes beyond just muscle mass preservation.
Source link
Losing Muscle with GLP-1 RAs? There May be a Drug for That
